# **Product** Data Sheet



## HTH-02-006

Cat. No.: HY-156397 Molecular Formula:  $C_{25}H_{29}IN_6O_3$ 

Molecular Weight: 588.44 AMPK Target:

Pathway: Epigenetics; PI3K/Akt/mTOR Storage:

Powder -20°C 3 years 4°C 2 years

In solvent -80°C 6 months

> -20°C 1 month

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (169.94 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.6994 mL	8.4970 mL	16.9941 mL
	5 mM	0.3399 mL	1.6994 mL	3.3988 mL
	10 mM	0.1699 mL	0.8497 mL	1.6994 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (4.25 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (4.25 mM); Clear solution; Need ultrasonic

# **BIOLOGICAL ACTIVITY**

Description HTH-02-006 is a NUAK2 inhibitor (IC<sub>50</sub>?=?126?nM). HTH-02-006 reduces levels of phosphorylated MYPT1 in HuCCT-1 cells.

HTH-02-006 inhibits YAP-driven cell proliferation, hepatomegaly and tumorigenesis. HTH-02-006 also has antifibrotic

protective effect<sup>[1][2]</sup>.

126?nM (NUAK2)[1] IC<sub>50</sub> & Target

#### **REFERENCES**

[1]. Yuan WC, et al. NUAK2 is a critical YAP target in liver cancer. Nat Commun. 2018 Nov 16;9(1):4834.

2]. Zhang T, et al. NUAK1 pro	omotes organ fibrosis via YAP and TGF-β/SMAD signaling. Sci Transl Med. 2022 Mar 23;14(637):eaaz4028.	
	Caution: Product has not been fully validated for medical applications. For research use only.	
	Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com	
	Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA	

Page 2 of 2 www.MedChemExpress.com